WDM(SH:600055)2024-03-22 16:00Financial Performance - The company's operating revenue for 2023 was CNY 1,236,669,630.89, representing a 10.30% increase compared to CNY 1,121,203,548.49 in 2022[29] - The net profit attributable to shareholders for 2023 was CNY 188,537,925.62, reflecting a 7.51% increase from CNY 175,369,143.35 in the previous year[29] - The net profit after deducting non-recurring gains and losses decreased by 13.32% to CNY 135,837,275.01 from CNY 156,705,092.25 in 2022[29] - The net cash flow from operating activities increased by 12.30% to CNY 208,218,005.65 compared to CNY 185,408,318.86 in 2022[29] - The total assets at the end of 2023 were CNY 5,396,325,530.54, a 2.54% increase from CNY 5,262,599,175.73 at the end of 2022[29] - The net assets attributable to shareholders at the end of 2023 were CNY 4,711,473,658.91, up 2.30% from CNY 4,605,403,996.79 in 2022[29] - The basic earnings per share for 2023 were CNY 0.269, a slight increase of 1.13% from CNY 0.266 in 2022[31] - The diluted earnings per share remained at CNY 0.269, unchanged from the previous year[34] - The weighted average return on equity for 2023 was 4.05%, a decrease of 0.32 percentage points from 4.37% in 2022[34] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 1.30 per 10 shares, totaling CNY 91,397,937.54, subject to shareholder approval[16] - The company plans to distribute cash dividends of 84.4 million CNY for the 2022 fiscal year, which has been executed[115] - The total dividend amount (including tax) was 84,367,326.96, representing 48.11% of the net profit attributable to ordinary shareholders[122] Non-Operating Income and Expenses - The company reported a total non-operating income of CNY 52,700,650.61 for the year 2023, with a significant portion attributed to government subsidies and fair value changes of financial assets[36] - The company recorded a decrease in trading financial assets by CNY 96,778,868.49, impacting the profit for the period by CNY -368,868.49[43] - The company reported a VAT refund amounting to CNY 36,786,258.38, which is expected to have a sustainable impact on its financials[49] - The company’s non-recurring losses from the disposal of non-current assets amounted to CNY -665,692.2 for the year 2023[41] - The company reported a fair value change loss of CNY 368,868.49 for other assets during the reporting period[71] Market and Product Development - The company achieved a total of 14 NMPA registration certificates for high-end products, enhancing its competitive product structure and supporting its transition to higher-tier hospitals[53] - The company successfully obtained EU MDR CE certification for seven product series, facilitating its expansion into the European market and accelerating its globalization efforts[53] - The company has launched multiple new models of its Direct Digital Radiology (DR) System, with certifications valid until June 2028[56] - The company has developed and registered multiple high-end CT products, focusing on cost reduction and efficiency improvements[175] - The company’s subsidiary, Wanli Cloud, achieved revenue of 124 million yuan, a year-on-year increase of 54%, serving over 7,000 hospitals[185] - The sales volume of 64-slice CT products increased by 80% year-on-year, entering the top ten in the market for 24-slice and 32-slice products[188] - The company ranked sixth in the total sales of superconducting MRI products in China, with stable growth in the private sector market[190] - The company completed the registration of CGO-5100 and CGO-5200, expanding its DSA product line and enhancing its market competitiveness[184] - The company plans to launch high-end MRI products to further enhance its market position in the MRI sector[190] - CT products have become the largest product line in terms of sales volume and revenue, with a diverse range of 15 products covering 24-slice to 32-slice configurations, meeting the needs of primary users[194] - The company successfully registered and launched 15 new products during the reporting period, including a 64-slice 128-layer product that provides comprehensive clinical examination coverage[194] - The digital gastrointestinal product line has maintained a leading position in the domestic market, with the DRF-8 series offering competitive functionality and higher cost performance compared to imported products[196] Research and Development - The company achieved a total R&D investment of 172 million yuan, accounting for 13.93% of the current operating revenue[175] - The total number of R&D personnel reached 289, representing 27% of the total workforce, indicating a continuous increase in R&D capacity[175] - The company has actively pursued technology innovation and market expansion, focusing on new product development and existing product improvements[45] Corporate Governance and Management - The company has appointed a new president, Song Jinsong, following the departure of former president Xie Yufeng[93] - The board of directors held its ninth meeting on April 17, 2023, where multiple reports, including the 2022 annual financial report, were approved[94] - The company has a total of 5 independent directors, ensuring compliance with governance standards[83] - The board has established specialized committees to enhance oversight and decision-making processes[85] - The company has a diverse board with members having extensive experience in various industries, including finance and healthcare[88] - The company has established a performance evaluation system to provide annual performance bonuses based on employee contributions[106] - The remuneration of directors and senior management is determined by the shareholders' meeting and the board of directors, respectively[81] Compliance and Risk Management - The internal control audit report issued by the auditing firm confirmed that the company maintained effective internal control over financial reporting in all material respects[125] - The company has not identified any significant or important control deficiencies in its internal control system during the reporting period[125] - The company has committed to avoiding competition with its subsidiaries and ensuring fair pricing in related transactions[141] - The company has confirmed that related party transactions do not significantly impact its independence[104] - The company has committed to maintaining independence in operations and financials, ensuring no non-operational fund occupation by controlling shareholders[144] - The company has not faced any major litigation or arbitration matters during the reporting period[167] - The company has not encountered any risks of delisting or termination of listing during the reporting period[157] Environmental and Social Responsibility - The company has implemented carbon reduction measures, including the use of clean energy for power generation[129] - The company has established a mechanism for environmental protection and is committed to fulfilling its social responsibility[137] - The company invested 1,850,000 in environmental protection funds during the reporting period[128] Strategic Planning - The company conducted a strategic planning meeting on August 28, 2023, approving the strategic plan for 2024-2026, including overall business goals and major product planning[110] - The company plans to complete the development of the Beijing MR R&D center and the Beijing CT manufacturing plant by 2024[65] - The company will focus on international market expansion, particularly in promoting CT products overseas and implementing localization strategies in key regions[75] - The company aims to enhance production efficiency by improving quality management systems and optimizing resource allocation[64] - The company has adopted a "sales-driven production" model, combining order-based and stock production to optimize production efficiency and ensure product quality[198]